m&m #4 6-7

OBLEJARNE
At the conclusion of this activity, the parti I CATEGORY 1 CME FOR
involved in neuropathic pain transmission; PHYSICIANS
The UCLA Neuropsychiatric Institute desig-
nates this educational activity for a maximum of 3 hours of Category 1 credit toward the California Medical Association's Certification • Identify clinical considerations when selecting an analgesic for treating chronic MANDATORY CONTINUING
• Discuss the integration of biopsychosocial EDUCATION FOR
PSYCHOLOGISTS
pharmacologic therapies into primary care now receive CME certificates for their contin- ACCREDITATION
EDUCATIONAL GRANTOR
This activity is supported by an unrestricted educational grant from Eli Lilly and Company.
for physicians. The UCLA Neuropsychiatric DISCLOSURE INFORMATION
content, quality and scientific integrity of It is the policy of the UCLA Neuropsychiatric Institute to ensure balance, independence, and scientific rigor in all educational activities.
Any significant financial interest or any other relationship a faculty member may have with product(s) or device(s) must be disclosed to the participants at the time of the activity.
The faculty has disclosed the following: Gary J. Bennett, PhD
of drugs. Not all agents and/or protocols Has received research grant support from: Endo Pharmaceuticals, Guilford Pharma-ceuti- approved by the FDA. Physicians should note cals Inc., Hypnion, Inc., Pfizer Inc.
that the use of these agents outside current approved labeling is considered experimental Avigen, Inc., Novartis Pharmaceuticals.
and are advised to consult current prescribing information for these products. The faculty is Michael Byas-Smith, MD
required to disclose their discussion of drugs Has reported no actual or potential conflict of or medical devices that are unlabeled, investi- interest in relation to this activity.
gational, or not approved for the use that is David A. Fishbain, MD
Has served as a consultant for Eli Lilly and Co.
The contributing faculty developed the content Has participated in speakers’ bureau for: independently. All materials are included with Lilly and Co., Endo Pharmaceuticals.
permission. The opinions expressed are those Scott M. Fishman, MD
of the faculty and are not to be construed as Has received research grant support from: those of the educational sponsor or grantor.
Elan Pharmaceuticals, Endo Pharmaceuticals, Faculty have disclosed the following: Janssen Pharmaceutica, Inc., Merck & Co., Inc., Pfizer Inc., Purdue Pharma, L.P.
Gary J. Bennett, PhD
Off-label uses of dextromethorphan, keta- Has served as a consultant for: Cephalon, Elan mine, amantadine, memantine, tricyclic antide- pressants, venlafaxine, lidocaine, tocainide, mexiletine, antiepileptics, ziconotide, ethosux- Inc., Merck & Co., Inc., Pfizer Inc., Purdue Has participated in speakers’ bureau for: Elan David A. Fishbain, MD
Off-label uses of fluoxetine, milnacipran, Janssen Pharmaceutica, Inc., Merck & Co., venlafaxine, tricyclic antidepressants, and Inc., Pfizer Inc., Purdue Pharma, L.P.
selective serotonin reuptake inhibitors are Rollin M. Gallagher, MD, MPH
Has served as a consultant for: Eli Lilly and Co., Scott M. Fishman, MD
Endo Pharmaceuticals, Janssen Pharmaceutica, Off-label uses of valproic acid, phenytoin, Has received research grant support from: Eli zonisamide, tricyclic antidepressants, selective serotonin reuptake inhibitors, dexamethasone, baclofen, capsaicin cream, clonidine, opioids, NLABELED USES/
INVESTIGATIONAL USES/
NOT YET APPROVED
COMMERCIAL PRODUCTS
The audience is advised that one or more
sections in this educational activity may contain references to unlabeled or unapproved uses

Source: http://www.mindsandmedicine.org/pdfs/neuropsychiatry/2005_Treatment_Chronic_Neuropathic_Pain_Faculty.pdf